WO2025229572 - EPSTEIN-BARR VIRUS ANTIGEN-ENCODING MESSENGER RIBONUCLEIC ACID AND ANTIGEN PROTEIN VACCINES
National phase entry is expected:
Publication Number
WO/2025/229572
Publication Date
06.11.2025
International Application No.
PCT/IB2025/054531
International Filing Date
30.04.2025
Title **
[English]
EPSTEIN-BARR VIRUS ANTIGEN-ENCODING MESSENGER RIBONUCLEIC ACID AND ANTIGEN PROTEIN VACCINES
[French]
VACCINS À BASE D'ACIDE RIBONUCLÉIQUE MESSAGER CODANT POUR L'ANTIGÈNE DU VIRUS D'EPSTEIN-BARR ET DE PROTÉINES ANTIGÉNIQUES
Applicants **
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors
BEITZEL, Brett F.
MARUGGI, Giulietta
BIANCUCCI, Marco
WIZEL, Benjamin
CHANDRAMOULI, Sumana
Priority Data
63/640,957
01.05.2024
US
63/644,548
09.05.2024
US
63/695,379
17.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5225 | |
| EPO | Filing, Examination, Granting | 33217 | |
| Japan | Filing, Examination, Granting | 3183 | |
| South Korea | Filing, Examination, Granting | 4168 | |
| USA | Filing, Examination, Granting | 14390 |
Total:
60,183
Contact Us
Abstract[English]
Provided are a pharmaceutical composition comprising a delivery vehicle and at least two Epstein-Barr virus (EBV) antigen-encoding messenger ribonucleic acid (mRNA) constructs. Methods of treatment, methods of making, uses of the pharmaceutical composition, and pharmaceutical compositions comprising at least two or more EBV antigens are provided. All contemplate treating and preventing (i.e. reducing the likelihood of a symptom or a severity of a symptom of) EBV infections and EBV-associated diseases, such as infectious mononucleosis, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.[French]
L'invention concerne une composition pharmaceutique comprenant un véhicule d'administration et au moins deux constructions d'acide ribonucléique messager (ARNm) codant pour l'antigène du virus d'Epstein-Barr (EBV). L'invention concerne des procédés de traitement, des procédés de fabrication, des utilisations de la composition pharmaceutique, et des compositions pharmaceutiques comprenant au moins deux antigènes d’EBV ou plus. Tous envisagent de traiter et de prévenir (c'est-à-dire de réduire la probabilité d'un symptôme ou la gravité d'un symptôme d') les infections par EBV et les maladies associées à l'EBV, telles que la mononucléose infectieuse, la sclérose en plaques, la polyarthrite rhumatoïde et le lupus érythémateux disséminé.